ARTICLE | Clinical News
Velcade bortezomib: Additional Phase III data
December 19, 2005 8:00 AM UTC
Extended survival data from median follow-up of 22 months of 669 evaluable patients from the international Phase III APEX trial showed that median overall survival with Velcade was 30 months vs. 24 mo...